-
Why This Analyst Thinks Gilead Sciences Will 'Handily' Beat Q4 Expectations
Tuesday, February 3, 2015 - 12:28pm | 277Read More...Gilead Sciences, Inc.'s (NASDAQ: GILD) strong sales of its hepatitis C drug will help it beat expectations when the company posts fourth-quarter earnings later today, an analyst said. "Gilead should beat earnings expectations handily" on strength in sales of its Sovaldi hepatitis...
-
December Payrolls Stronger Than Expected, November Revised Higher
Friday, January 9, 2015 - 10:17am | 307Read More...Total nonfarm payroll employment rose to 252,000 in December (against the 240,000 consensus estimate), and the unemployment rate declined to 5.6 percent, as reported by the U.S. Bureau of Labor Statistics. Job gains occurred in professional and business services, construction, food services and...
